ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2023GlobeNewsWire • 05/11/23
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2023GlobeNewsWire • 05/04/23
ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2022GlobeNewsWire • 02/21/23
ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2022GlobeNewsWire • 02/15/23
ImmuCell Announces Preliminary, Unaudited Sales Results for the Year Ended December 31, 2022GlobeNewsWire • 01/09/23
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2022GlobeNewsWire • 11/21/22
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2022GlobeNewsWire • 11/10/22
ImmuCell Announces Preliminary, Unaudited Sales Results for Third Quarter of 2022GlobeNewsWire • 10/05/22
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/12/22
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2022GlobeNewsWire • 08/11/22
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2022GlobeNewsWire • 08/04/22
ImmuCell Receives Technical Section Incomplete Letter from FDA Pertaining to Re-Tain®GlobeNewsWire • 07/28/22
ImmuCell Announces Preliminary, Unaudited Sales Results for Second Quarter of 2022GlobeNewsWire • 07/07/22
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/13/22
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2022GlobeNewsWire • 05/12/22
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2022GlobeNewsWire • 05/10/22
UPDATE -- Dr. Mark Wustenberg joins ImmuCell as Commercial Leader of Stakeholder EngagementGlobeNewsWire • 05/05/22
Dr. Mark Wustenberg joins ImmuCell as Commercial Leader of Stakeholder EngagementGlobeNewsWire • 05/05/22